Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03405142 · ClinicalTrials.gov registry record · Phase 2

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

A Phase 2 study, sponsored by Eben Rosenthal.

Completed
Registry status
Phase 2
Development phase
3
Enrollment target

NCT03405142: Completed Phase 2 study, sponsored by Eben Rosenthal.

NCT03405142 is a Phase 2 study that has completed, run by Eben Rosenthal. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03405142, a Phase 2 study, has completed, sponsored by Eben Rosenthal.

COMPLETED
Registry status
Phase 2
Development phase
3 participants
Enrollment target

Study Summary

This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.

Primary Outcome

After administration of panitumumab-IRDye800 alone or with Lymphoseek, lymph nodes potentially containing malignant tumor cells were surgically removed, and the lymph node tissue was evaluated for panitumumab-IRDye800 fluorescence intensity. For each subject, the 5 lymph nodes with the strongest fluorescence signal were tabulated against the Lymphoseek and histopathologic findings for those specific lymph nodes. For each of the 3 modalities, a positive finding is considered indicative of maligna

Interventions

  • DRUG Panitumumab-IRDye800
  • DRUG Lymphoseek

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2019-08-01
Est. Completion 2021-04-27
Phase Phase 2
Eben Rosenthal

8 total trials

What the finished NCT03405142 record still lists

NCT03405142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Panitumumab-IRDye800 is the first listed.

NCT03405142 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03405142 about?

NCT03405142 is a clinical study titled "Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer". This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or l...

What is the current status of trial NCT03405142?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-01. Estimated completion is 2021-04-27.

What interventions are being tested in trial NCT03405142?

The interventions under investigation include: Panitumumab-IRDye800 (DRUG), Lymphoseek (DRUG).

Who is sponsoring clinical trial NCT03405142?

This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03405142's enrollment target sits among peer trials

3 2001st of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03405142, the US trial registry maintained by the National Library of Medicine. NCT03405142 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.